Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Konstantin Ichtchenko
New York University School of Medicine, Department: Biochemistry
Should you be removed from our database? Contact us at [email protected]. Read more below.
CytoDel, LLC
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
CytoDel is a company formed around a technology associated with genetically engineered botulinum toxins. The company’s purpose is to improve therapeutics, cosmetic indications, and drug delivery directly to neurons. Dr. Ichtchenko's research appears to be related to the technology licensed to CytoDel.
Novel therapeutic approaches to treatment of botulinum neurotoxin poisoning
Project Narrative The goal of this project is to create anti-botulinum neurotoxin therapeutics and to test these therapeutics for efficacy and toxicity in model assays and in preclinical in vivo systems. This project provides product-ready alternatives to currently existing treatment modalities, including passive immunotherapy and vaccination, which have well described limitations. It is recognized that a large botulism outbreak would be disastrous due to lack of sufficient numbers of ICUs equipped with mechanical ventilators for prolonged life support, and the lack of an antidote that is effective after the toxin has entered neuronal cells (24-48 hours after intoxication), which emphasizes the need for a therapeutics that can treat botulism by inactivating BoNT after neuronal entry.
Filed on December 06, 2016.
Tell us what you know about Konstantin Ichtchenko's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Konstantin Ichtchenko filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Konstantin Ichtchenko | New York University School of Medicine | Conflict of Interest | CytoDel, LLC | $200,000 - $249,999 |
| Konstantin Ichtchenko | New York University School of Medicine | Conflict of Interest | CytoDel, LLC | $20,000 - $39,999 |
| Konstantin Ichtchenko | New York University School of Medicine | Conflict of Interest | CytoDel, LLC | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.